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Abstract
Human platelets are derived from megakaryocytes as anu-
cleate cells, and thus contain only vestigial amounts of RNA
capable of being transcribed into protein. This has greatly
hampered efforts to study directly platelet-specific gene prod-
ucts and their associated polymorphisms. In this report, we
describe direct amplification, using the polymerase chain reac-
tion, of platelet-derived mRNA in amounts sufficient to permit
detailed analysis, such as restriction mapping and nucleotide
sequencing. The ability to generate large amounts of cDNA
from platelet-specific mRNA sequences should make possible
direct molecular characterization of normal platelet proteins,
and facilitate the investigation of a wide variety of inherited
platelet disorders.
Introduction
Human platelets contain more than 40 identifiable membrane
protein constituents, many of which have yet to be character-
ized. Since platelets are derived from megakaryocytes as non-
nucleated cells, it is generally believed that they possess only
vestigial amounts of protein-synthetic capability, although
specific protein biosynthesis in platelets has been demon-
strated ( 1-3 ). A primary deterrent to investigating the primary
structure of platelet-specific gene products has therefore been
the inability to obtain sufficient platelet mRNA to produce
cDNA libraries. A number of nucleated cell types have re-
cently been shown to synthesize proteins that are biochemi-
cally and immunologically related to their platelet counter-
parts (for a review, see reference 4), and cDNA libraries con-
structed from these cells have been used to obtain the
nucleotide sequences of several platelet protein analogues
(5-8). Since these sequences are deduced from cDNA clones
derived from either transformed cell lines or cells of nonmega-
karyocytic lineage, the possibility remains that the protein se-
quence of the actual platelet counterpart differs somewhat
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from that of the analogue found in the nucleated cell from
which the sequence was derived.
It would be desirable to be able to study platelet-specific
gene sequences for a number ofother reasons. Platelets express
a number of polymorphic epitopes on their surface that play
an important role in the etiology of alloimmune platelet dis-
orders (9, 10), and the molecular definition of alloantigenic
determinants would contribute to our understanding of the
morphological features of platelet antigens that are responsible
for eliciting an alloimmune response. These and other interest-
ing platelet-related polymorphisms are often present in low
frequency in the human population, making it nearly impossi-
ble to predict or regulate the phenotypic makeup of a non-
platelet cDNA library. A preliminary report ( 11) suggests that
platelet mRNA can be prepared from individuals with myo-
proliferative disorders in sufficient quantities to permit con-
struction of a platelet-specific cDNA library, but it too would
be limited in the number of polymorphic phenotypes repre-
sented.
Recently, a method to enzymatically amplify short seg-
ments of DNA has been developed (12-16). Known as the
polymerase chain reaction (PcR),' this technique uses two
oligonucleotide primers to direct the repeated synthesis of
DNA bounded by their respective complementary sequences.
Since PcR has been reported to be capable of amplifying spe-
cific DNA sequences > 10 times, we decided to explore using
this method in the amplification of the vestigial amounts of
mRNA present in human platelets. In this report, we demon-
strate that the RNA that can be derived from the platelets
present in 50 ml of whole blood from normal individuals is
sufficient to produce microgram quantities of platelet-specific
cDNA. This DNA is readily amenable to further detailed anal-
ysis, including restriction mapping, subcloning, and nucleo-
tide sequencing.
Methods
Materials. Taq DNA polymerase isolated from Thermus aquaticus
was purchased from Perkin-Elmer Corp., Instrument Div., Norwalk,
CT. PGE,, Sarkosyl, and Antifoam A were obtained from Sigma
Chemical Co., St. Louis, MO. Agarose used for preparative electropho-
resis was GTG-grade supplied by FMC Corp. Bioproducts, Rockland,
ME. Placental RNAse inhibitor (RNAsin) was purchased from Pro-
mega Biotec, Madison, WI. Guanidinium isothiocyanate and cesium
1. Abbreviations used in this paper: GP, glycoprotein; PcR, polymer-
ase chain reaction; PRP, platelet-rich plasma.
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chloride were purchased from Bethesda Research Laboratories, Gaith-
ersburg, MD. Southern blot hybridization was performed after transfer
to Genescreen Plus nylon membranes (Dupont Co., Diagnostic and
BioResearch Systems, Wilmington, DE). All other chemicals used
were of reagent grade.
Isolation of platelet RNA. Human platelets were isolated from
whole blood as previously described (17). Briefly, 50 ml of venous
blood collected from healthy volunteer donors was anticoagulated with
7 ml of acid citrate dextrose (National Institutes of Health, Formula
A), and PGEI was added to a final concentration of 50 nmol/liter.
Platelet-rich plasma (PRP) was prepared by differential centrifugation,
and the platelets present in the upper half of the PRP were harvested
and washed an additional two times in wash buffer (100 mmol/liter
NaCl, 8.5 mmol/liter Tris, 8.5 mmol/liter glucose, and 1 mmol/liter
Na2EDTA, pH 7.4). By carefully avoiding the lower half of the PRP,
we were consistently able to achieve a platelet/leukocyte ratio of at
least 3000:1. The final platelet pellet was solubilized in 3.3 ml of buffer
composed of 4 mol/liter guanidinium isothiocyanate, 5 mmol/liter
sodium citrate, 0.1 mol/liter 2-mercaptoethanol, 0.5% Sarkosyl, 0.1%
Antifoam A, and 40 U/ml placental RNAse inhibitor, layered onto a
1.2-ml cushion of 5.7 mol/liter CsCl, and centrifuged at 20'C in a
TiSO. 1 rotor at 35,000 rpm for 16 h (Beckman Instruments, Inc. Ful-
lerton, CA). The nearly invisible RNA pellet was resuspended in
buffer made up of 10 mmol/ liter Tris, 5 mmol/ liter EDTA, and 1%
SDS, pH 7.4), extracted with chloroform/butanol, and ethanol precip-
itated essentially as described by Maniatis et al. (18). The resulting
purified total platelet RNA fraction recovered using this technique was
<1 gg per individual, and was used in all subsequent steps without
further fractionation.
Oligonucleotides. Based upon the published nucleotide sequence of
platelet membrane glycoprotein (GP) Ila (5), two oligonucleotide
primers were constructed such that they would be - 1 kb apart in the
mRNA sequence. All oligonucleotides used in this study were con-
structed by The Blood Center of Southeastern Wisconsin Molecular
Biology Core Laboratory (Milwaukee, WI) with a Gene Assembler
(Pharmacia Fine Chemicals, Piscataway, NJ) using standard ft-cyan-
oethyl phosphoramidite chemistry. Oligonucleotides were purified by
preparative gel electrophoresis on sequencing gels followed by Sepha-
dex G-25 (Pharmacia Fine Chemicals) chromatography. The oligo
PcR-l corresponded to the RNA strand from nucleotides 1,1 16-1,138
of the published sequence (5), whereas oligo PcR-2 corresponded to
the antisense strand at nucleotides 2,201-2,177. The sequences of
these primers are shown in Table I, with their locations relative to the
coding sequence of GPIIIa cDNA illustrated in Fig. 1. The region
bounded by these two oligonucleotides, while only 1,085 bases apart in
the mRNA sequence, is known to span > 5 kb of genomic DNA,
encompassing no less than three introns (L. Fitzgerald, Gladstone
Foundation Laboratories, personal communication). The oligonucle-
otide primers correspond to unique sequences present in GPIIIa that
are not present in related members of the integrin family of cytoadhe-
sive glycoprotein receptors such as the leukocyte very late activation
(VLA) antigens, LFA-1, or the fibronectin receptor (4-6). The speci-
ficity of each oligonucleotide was verified by Southern blot hybridiza-
tion to DNA inserts of known identity (see below).
Amplification ofthe platelet GPIIIa RNA sequence. Total platelet
RNA from each individual was resuspended in 28.7 Ml of diethylpyro-
carbonate-treated, sterile water in a sterile, siliconized, diethylpyrocar-
bonate-treated 0.5-ml polypropylene tube. cDNA synthesis was per-
formed directly in this tube using cloned M-MLV reverse transcriptase
and a cDNA synthesis kit (Bethesda Research Laboratories) according
to the manufacturer's directions, except that the oligonucleotide
primer PcR-2 was substituted for Oligo (dT)12-18 to direct only
GPIIIa-specific first strand synthesis. The first strand reaction mix
contained 50 mmol/liter Tris pH 8.3, 75 mmol/liter KCI, 3 mmol/
liter MgCl2, 10 mmol/liter DTT, 0.5 mmol/liter each of dATP,
dGTP, dCTP, and dTTP, 1.0 Mmol/liter PcR-2 oligonucleotide, and
500 U M-MLV reverse transcriptase, in a final volume of 50 Ml. cDNA
synthesis was carried out at 370C for 60 min, at which time the reac-
tion was stopped by chilling to 0C. The first strand reaction mix was
diluted with an equal volume of PcR dilution buffer (25 mmol/liter
KCI, 1 umol/liter PcR2 oligonucleotide, 2 Mmol/liter PcR-I oligonu-
cleotide, and 0.02% gelatin) and heated to 94°C for 2 min to separate
the strands. Samples were allowed to cool to 37°C, at which time 1 Al
(5 U) of Taq polymerase was added to initiate the polymerase chain
reaction. Amplification was performed for 30 cycles, with 10-min
primer extensions at 72°C, denaturation for 1 min 20 s at 94°C, and
primer annealings for 3 min 20 s at 37°C. An additional 2.5 U of Taq
polymerase was added after cycles 10 and 20. After the PcR, the am-
plified samples were stored at -20°C.
Analysis of PcR reaction products. 10-15 Ml of each 100-Mul PcR
reaction was analyzed on a 1% agarose gel, followed by staining with
ethidium bromide. Positive identification of the resulting DNA bands
as authentic derivatives of the mRNA encoding GPIIIa was obtained
by Southern blot analysis, using a cloned GPIIIa insert that runs from
base 45 of the published sequence ( 5) to the internal Eco RI site at base
2,274. This GPIIIa clone, termed 52, was obtained from a Xgtl 1 ex-
pression library (kindly provided by Dr. C.-J. Edgell, University of
North Carolina, Chapel Hill, NC) made from the permanent endothe-
lial cell/lung carcinoma hybrid cell line, EA * hy 926, (19). The iden-
tity of clone 52 was verified by both restriction mapping and compari-
son of its nucleic acid sequence (not shown) with that of the published
sequence for GPIIIa. Southern blots were hybridized at 68°C for 16 h
with a "P-labeled nicktranslated ptZ18r plasmid (Pharmacia Fine
Chemicals) that contained the clone 52 insert, washed at high strin-
gency (0.1 X SSC, 68°C), and exposed to Kodak X-AR film for 15-
30 min.
To further characterize the PcR reaction products, amplified DNA
bands of the expected size were recovered from agarose gels using an
electroeluter (model UEA; International Biotechnologies Inc., New
Haven, CT) and subjected to limited restriction map analysis. Selected
restriction fragments were subcloned into the plasmid vector
pGEM-7Zf (Promega Biotec) and subjected to nucleotide sequence
analysis.
Results
Amplification of the GPIIIa mRNA. As an example of the
utility ofPcR in amplifying platelet-specific mRNAs, we chose
to perform our initial studies using the well-characterized
GPIIIa molecule. The amplification strategy to produce a
platelet-specific cDNA is depicted in Fig. 1. To facilitate analy-
sis of the PcR reaction products, two oligonucleotide primers,
PcR-l and PcR-2, were constructed such that they would: (a)
complement sequences specific for GPIIIa, and (b) flank a
Table I. Oligonucleotides Corresponding to Platelet-specific Sequences Used in cDNA Synthesis and PcR Amplification
Primer Sequence location in GPIIIa DNA strand Sequence (5'- - -> 3)
PcR-l 1,116-1,138 RNA GTCCTCCAGCTCATTGTTGATGC
PcR-2 2,201-2,177 Anti-sense CATCACTGAGAGCAGGACCACCAGG






Figure 1. Diagramatic representation of the GPIIIa mRNA mole-
cule. The locations of the two PcR oligonucleotide primers, the re-
gion encoding the putative transmembrane domain (Trans), the
unique Bam HI restriction site, and the predicted 1-kb section of the
amplified GPIIIa cDNA (bottom) are illustrated.
unique Bam H1 restriction endonuclease site. The relatively
large 1,000-bp distance between the two oligonucleotides was
chosen to provide a stringent test of the specificity and overall
utility of PcR in amplifying the minute amounts of vestigial
RNA present in human platelets. As shown in Fig. 2, large
amounts of a 1-kb cDNA were produced during the PcR (lane
A). Also evident were lesser amounts of smaller sized cDNA's.
Most of these probably represent sites of nonspecific priming
on other platelet RNAs, although a few bands may represent













Figure 2. Identification and characterization of the cDNA molecule
amplified from platelet mRNA. Total platelet RNA derived from 50
ml of blood was enzymatically amplified in the presence of the oligo-
nucleotide primers, PcR-l and PcR-2, using Taq polymerase for 30
cycles in a total reaction volume of 100 gl. After PcR, 15 Ml of the re-
action mixture was analyzed on a 1% agarose gel, and the resulting
bands visualized by ethidium bromide staining (lane A). Lane B is
an autoradiograph of a Southern blot of the same gel that had been
hybridized with a nick-translated plasmid containing a GPIIIa insert.
The remaining 85 Ml of the PcR reaction mix was subjected to pre-
parative agarose gel electrophoresis, and the 1-kb band excised and
recovered by electroelution. 20% of this material was digested with
Bam H 1, resulting in restriction fragments of the expected sizes
(lane C).
Characterization of the 1-kb cDNA produced during PcR.
To identify the major band (Fig. 2, lane A) as a GPIIIa cDNA,
the same ethidium bromide-stained gel was further analyzed
by Southern blot hybridization. As shown in Fig. 2, lane B, the
major band formed during PcR hybridized strongly with the
GPIIIa-specific probe. Several, but not all, of the minor PcR
reaction products also hybridized with the probe, suggesting
that they may represent incomplete or partially degraded
GPIIIa cDNAs. The remaining PcR bands did not show spe-
cific hybridization, and may have formed as a result of the
relatively low temperature (370C) used during the primer an-
nealing step of the PcR.
To provide further evidence that the major cDNA pro-
duced during PcR was an authentic amplified copy of the
region of GPIIIa bounded by the oligonucleotides PcR- 1 and
PcR-2, the band at 1 kb that had hybridized with the known
GPIIIa cDNA insert was excised from a preparative agarose
gel, purified by electroelution, and digested with the restriction
endonuclease Bam H1. Two discrete fragments, migrating at
384 and 701 bp, resulted from this digestion (Fig. 2, lane C).
These bands correspond exactly to the predicted sizes (see Fig.
1), and together with the hybridization data, positively identify
the major product of the PcR reaction as the expected segment
ofcDNA encoding platelet GPIIIa. Nucleotide sequence anal-
ysis of the two restriction fragments (not shown) confirmed
these results.
Discussion
We have described a new approach for studying directly plate-
let mRNA sequences that encode platelet-specific gene prod-
ucts. Our strategy is based on the use of the PcR, which has
been shown to be capable of enzymatically amplifying short
segments of DNA (12-16). To adapt the amplification tech-
nique to the study of platelet-specific proteins, we had to con-
vert platelet-specific mRNA into cDNA before performing
PcR. The amount of platelet RNA that can be recovered from
50 ml of blood from normal individuals is exceedingly small,
thus both RNA and cDNA preparation were performed using
samples that could not generally be visualized. Using two oli-
gonucleotide primers that flank a 1-kb region present in plate-
let GPIIIa, however, we were able to synthesize, in vitro, mi-
crogram amounts ofa specifically targeted region ofthe GPIIIa
cDNA molecule. That the resulting amplified cDNA repre-
sented an authentic copy of platelet GPIIIa cDNA was demon-
strated by hybridization to a well-characterized specific probe,
and by the generation of restriction fragments diagnostic for
the specific region of the GPIIIa cDNA under investigation.
Subsequent nucleotide sequence analysis of the amplified seg-
ment confirmed these results.
The ability to amplify specific sequences 10-_106 times
affords a level of sensitivity heretofore unavailable for investi-
gating the presence of small quantities of distinct mRNAs in
individual cell types. This capability will undoubtedly lead to
the discovery that proteins once thought to be cell- or tissue-
specific are present in previously undetectable quantities in
other cell types. For example, there is presently no consensus,
based upon extensive immunochemical analysis from a num-
ber of laboratories, as to whether peripheral blood monocytes
actually synthesize small amounts of GPIIIa, or merely appear
to express it on their surface as a result of contamination with
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adherent platelets or platelet fragments (4). Northern blot
analysis of monocyte mRNA, however, failed to demonstrate
specific messages encoding either GPIIb or GPIIIa (8). There-
fore, if monocytes contain GPIIb/GPIIIa mRNAs, they are
present at levels below those which are detectable by northern
blot analysis. Using the techniques presented here, questions
such as these can now be directly addressed.
Current methods for purifying platelets by differential cen-
trifugation are incapable of yielding absolutely leukocyte-free
preparations. Although there are currently no convincing data
that GPIIIa is expressed in any leukocyte subpopulation, it
cannot yet be excluded that our platelet RNA preparation
contains some proportion of monocyte, neutrophil, and lym-
phocyte RNA, and that a small percentage of the amplified
GPIIIa cDNA could be derived from leukocyte mRNA. That
the majority of the RNA is of platelet origin, however, is sup-
ported by the fact that our laboratory has also been successful
in amplifying from our platelet RNA preparations vWfcDNA,
which encodes a protein found exclusively in endothelial cells
and platelets (20) (Friedman, K., P. Newman, J. Rayner, and
R. Montgomery, unpublished observations).
The discovery that platelet-specific mRNA sequences can
be amplified using PcR is applicable to a wide variety of topics
related to platelet morphology and physiology. For example,
the mere fact that platelets contain mRNA sequences that can
be amplified strongly supports the evidence obtained by others
(1-3) that platelets retain the ability to synthesize small
amounts of protein. It would be interesting to see if all platelets
have this capability, or whether the presence of RNA is re-
stricted to young platelets recently released from bone marrow
megakaryocytes. If the latter is the case, PcR might be used to
investigate questions of platelet aging, such as the relationship
between platelet size, age, and density. Another anticipated
application of PcR technology to the study of platelet patho-
physiology might be genotypic analysis and diagnosis of
Glanzmann's thrombasthenia, including defining the molecu-
lar basis of several thrombasthenic variants that have been
reported (21, 22). Similarly, since there is some question as to
the biosynthetic source of several platelet a-granule proteins,
i.e., that platelets may be capable of acquiring plasma proteins
through an endocytotic pathway (2, 23, 24), PcR could also be
used to assess the ability of platelets, or indirectly megakaryo-
cytes, to specifically synthesize individual platelet compo-
nents.
Of particular interest to us is the potential applicability of
PcR towards defining platelet-specific polymorphisms that re-
sult in allo- and auto-immune thrombocytopenias. PcR would
appear to be the method of choice for analyzing relatively
infrequent polymorphic DNA sequences, since it enables one
to analyze specific sequence variations from a number of indi-
viduals without the need for cloning or constructing multiple
cDNA libraries. The relative simplicity of the DNA amplifica-
tion technique, together with the ability to now analyze plate-
let-specific sequences, should make possible the direct molecu-
lar characterization of normal platelet proteins and facilitate
the investigation of a variety of inherited platelet disorders.
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